NewEdge Advisors LLC Has $86,000 Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

NewEdge Advisors LLC increased its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 600.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,910 shares of the company’s stock after purchasing an additional 3,352 shares during the period. NewEdge Advisors LLC’s holdings in Cellebrite DI were worth $86,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CLBT. JPMorgan Chase & Co. grew its position in shares of Cellebrite DI by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock worth $7,202,000 after buying an additional 75,092 shares during the period. Harbor Capital Advisors Inc. grew its holdings in Cellebrite DI by 65.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock valued at $3,473,000 after purchasing an additional 62,320 shares during the period. Raymond James Financial Inc. bought a new stake in Cellebrite DI in the fourth quarter valued at approximately $9,995,000. Teacher Retirement System of Texas acquired a new stake in Cellebrite DI in the fourth quarter worth $442,000. Finally, New York State Common Retirement Fund boosted its position in shares of Cellebrite DI by 2.6% during the fourth quarter. New York State Common Retirement Fund now owns 189,599 shares of the company’s stock worth $4,177,000 after purchasing an additional 4,838 shares in the last quarter. 45.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Lake Street Capital raised their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Buy” and an average price target of $23.43.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $20.14 on Friday. The stock has a 50-day simple moving average of $18.82 and a 200 day simple moving average of $20.19. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The company has a market cap of $4.82 billion, a PE ratio of -14.49, a PEG ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.